Details for Patent: 8,901,123
✉ Email this page to a colleague
Which drugs does patent 8,901,123 protect, and when does it expire?
Patent 8,901,123 protects TABRECTA and is included in one NDA.
This patent has forty-nine patent family members in thirty-one countries.
Summary for Patent: 8,901,123
| Title: | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,- 4]triazin-2-yl]benzamide and processes related to preparing the same |
| Abstract: | The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin- -2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-- 2-yl]benzamide, and salts thereof. |
| Inventor(s): | Weng; Lingkai (Malvern, PA), Qiao; Lei (Downingtown, PA), Zhou; Jiacheng (Newark, DE), Liu; Pingli (Newark, DE), Pan; Yongchun (Newarl, DE) |
| Assignee: | Incyte Corporation (Wilmington, DE) |
| Application Number: | 13/793,864 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,901,123
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis Pharm | TABRECTA | capmatinib hydrochloride | TABLET;ORAL | 213591-001 | May 6, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | USE FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING MUTATION | ⤷ Try a Trial | ||||
| Novartis Pharm | TABRECTA | capmatinib hydrochloride | TABLET;ORAL | 213591-002 | May 6, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | USE FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING MUTATION | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,901,123
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 071873 | ⤷ Try a Trial | |||
| Argentina | 111428 | ⤷ Try a Trial | |||
| Argentina | 123240 | ⤷ Try a Trial | |||
| Australia | 2009249154 | ⤷ Try a Trial | |||
| Brazil | PI0912882 | ⤷ Try a Trial | |||
| Canada | 2724742 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
